Intravascular lymphomas are rare and aggressive hematolymphoid tumors. Here, we describe a human herpesvirus type-8 (HHV-8)/Kaposi sarcoma-associated herpesviruspositive and Epstein-Barr virus (EBV)-positive intravascular lymphoma. The patient was a 59-year-old human immunodeficiency virus-positive man who presented with diarrhea, abdominal pain, fevers, night sweats, and weight loss. Radiographic studies of the abdomen and pelvis revealed numerous subcentimeter nodules within the subcutaneous fat that lacked connection to the skin. An excisional biopsy demonstrated large atypical cells within vessels in the deep subcutaneous fat, and many of the vessels contained extensive organizing thrombi. The atypical cells lacked strong expression of most B-cell markers but were positive for MUM-1 and showed partial expression of several T-cell markers. An immunohistochemical stain for HHV-8 and an in situ hybridization for EBV were both positive in the neoplastic cells. The disease had a rapidly progressive and fatal course. This lymphoma appears to represent an entirely intravascular form of primary effusion lymphoma and highlights the propensity for HHV-8 and EBV-positive lymphoid neoplasms to show aberrant expression of T-cell markers, illustrates the utility of skin biopsies for the diagnosis of intravascular lymphoma, and suggests that biopsies to evaluate for intravascular lymphoma should be relatively deep and include subcutaneous fat.
BACKGROUND
Several lymphoproliferative disorders (LPDs) are associated with coincident Epstein-Barr virus (EBV) and human herpesvirus type-8 (HHV-8)/Kaposi sarcomaassociated herpesvirus infection, including primary effusion lymphoma (PEL), [1] [2] [3] [4] extracavitary PEL, [5] [6] [7] [8] [9] germinotropic lymphoproliferative disorder, 10 and some cases of plasmablastic Castleman disease [11] [12] [13] [14] (Table 1) . These disorders can be diagnostically challenging because of their relative rarity, characteristic lack of expression of typical B-cell markers, and occasional aberrant expression of T-cell antigens. 1, 4, 6, 15 They are more common in immunocompromised patients and usually occur in the setting of human immunodeficiency virus (HIV) infection but have also been reported in transplant patients 16, 17 and the elderly. 8, 15 In addition, there are rare reports of some of EBV-positive and HHV-8-positive LPDs occurring in the absence of immunodeficiency. 10, 18 Intravascular large B-cell lymphomas (IVLBCLs) are also rare. IVLBCL is usually widely disseminated but characteristically spares lymph nodes. The disease is aggressive, and the tumor cells occlude small vessels and capillaries causing end-organ ischemia. Different organs can be affected, leading to the protean presentation of IVLBCL; however, 2 major patterns of disease are recognized. A Western form presents with predominantly cutaneous or neurological symptoms, often in conjunction with B symptoms including fever, weight loss, and night sweats. An Asian variant of IVLBCL is associated with multiorgan failure, hepatosplenomegaly, pancytopenia, hemophagocytic syndrome, and B symptoms. 1, 19, 20 Here, we describe a case of intravascular lymphoma associated with EBV and HHV-8 coinfection, which to our knowledge has not been previously described. The clinical presentation and pathologic features of this unusual lymphoma highlight challenges in the diagnosis both of intravascular lymphomas and of neoplasms with HHV-8 and EBV coinfection.
MATERIALS AND METHODS
Formalin-fixed and paraffin-embedded tissue was subjected to hematoxylin and eosin staining as well as immunohistochemical staining and in situ hybridization (ISH) using routine methods. HHV-8 latent nuclear antigen (LANA-1), the product of the viral gene open reading frame 73, was detected using the 13B10 monoclonal antibody (Leica Systems; NCL-HHV8) at a standard dilution of 1:50. EBV was detected using an ISH probe against EBER (Ventana; 760-1209 DNP Probe) and was used prediluted, as received. Viral interleukin 6 (IL-6) staining was performed using a polyclonal rabbit antiserum raised against viral IL-6 peptides as previously described. 21 All other immunohistochemical staining analyses were performed using routine methods for clinical diagnosis.
Flow cytometric immunophenotyping was performed on fresh tissue. The material was dissociated by passing it through wire mesh, and the cell suspension was incubated with a combination of 4 monoclonal antibodies specific for CD19, CD3, k, and l (Becton Dickinson, San Jose, CA) that were titrated for optimal staining according to standard protocol.
Analysis for B-cell clonality by immunoglobulin heavy chain (IgH) gene rearrangement and T-cell clonality by T-cell receptor (TCR)-g gene rearrangements were performed in the Johns Hopkins molecular pathology facility according to established protocols for clinical use. Slices of formalin-fixed, paraffin-embedded tissue were extracted with xylene and absolute ethanol. DNA was prepared using the QiaAMP DNA Mini kit (Qiagen, Valencia, CA) according to the manufacturer's directions and subjected to polymerase chain reaction (PCR) using degenerate consensus primers to amplify the hyper-variable (VDJ) region of the IgH gene from the 3 0 end of the V region to the 3 0 end of the J region. The primers used were as follows: FR3A (directed at the 3 0 end of the V region) 5 0 -ACACGGCYSTGTATTACTGTG-3 0 and VLJH (directed at the 3 0 end of the J region) 5 0 -GTGACCAGGGTNCCTTGGCCCCAG-3 0 , where Y = C or T, S = G or C, and N = C, T, G, or A. In the presence of a monoclonal population, this amplification results in a distinct 50 to 150 bp product. Amplification of the b-globin gene was used as an internal control to ensure sufficient DNA quality and amplification. PCR amplified products were subjected to gel electrophoresis for analysis of clonal bands. TCR-g gene rearrangement was evaluated using the TCRG Gene Clonality Assay (Invivoscribe Technologies Inc.) according to the manufacturer's instructions.
CASE REPORT
A 59-year-old HIV-positive man presented with a 3-week history of diarrhea, abdominal pain, fevers, night sweats, dizziness, an unintentional 30-pound weight loss, and recent cognitive decline. The patient had been diagnosed with HIV 27 years before and was on highly active antiretroviral therapy. The patient was not taking any medications requiring subcutaneous injection for administration, and he denied intravenous drug use. Physical examination showed no evidence of skin lesions or lymphadenopathy.
Computed tomography scans of the chest, abdomen, and pelvis demonstrated that the spleen was enlarged, but no significant lymphadenopathy or masses were seen. The computed tomography scans were remarkable for numerous subcentimeter nodules scattered through the subcutaneous fat that did not show a connection to the overlying epidermis ( Fig. 1 ). These nodules showed mildly increased fluorodeoxyglucose uptake on a positron emission tomography scan. Laboratory values on admission were notable for mild anemia (Hb 10.7 g/dL; normal range, 13.9 to 16.3 g/dL) and thrombocytopenia (69k/mm 3 ; normal range, 150 to 350k/mm 3 ) with increased neutrophils (83%; normal range, 31% to 76%) and decreased lymphocytes (3%; normal range, 24% to 44%). The CD4 count was 526/mm 3 (normal range, 458 to 1344/mm 3 ), and the HIV-1 viral load was 93 copies/mL. The patient also had an increased lactic dehydrogenase (1329 U/L; normal range, 118 to 273 U/L).
A bone marrow biopsy that was performed 4 days before admission at an outside hospital showed hypercellular marrow with trilineage hematopoiesis and increased polyclonal plasma cells with no evidence of lymphoma. Colon biopsies demonstrated severe acute colitis but were negative for fungi, cytomegalovirus, and viral cytopathic effect. An initial fine-needle biopsy of a subcutaneous nodule demonstrated large, atypical cells suggestive of malignancy, but the material in the scant specimen was insufficient for a diagnosis.
A subsequent excisional biopsy of one of the subcutaneous nodules in the abdominal wall showed fibroadipose tissue with a patchy mixed inflammatory infiltrate and occasional hemosiderin-laden macrophages. Many of the vessels contained organizing thrombi, and some also contained large atypical cells. The atypical cells had a moderate amount of eosinophilic cytoplasm and round to oval nuclei with 1 or more prominent nucleoli (Fig. 2 ). There were numerous apoptotic bodies and mitotic figures seen within the vessels.
A panel of immunohistochemical stains and ISH for EBV (EBER) demonstrated that the atypical cells were positive for MUM-1, CD43, HHV-8 (LANA-1), EBV, and viral IL-6, with dim expression of CD79a and CD45 (Fig. 3) . A subset of the atypical cells expressed dim CD4, CD45-RO, and cytoplasmic CD3. The atypical cells were restricted to the intravascular compartment and had a high Ki-67 proliferation index. The B-cell markers CD20, CD19, and Pax-5 as well as the plasma cell markers CD138 and CD38 were negative in the neoplastic cells. Immunostains for IgG, IgM, and IgA were difficult to interpret because of high background staining, but many of the atypical cells appeared to express IgG. Immunostains for k and l light chains were noncontributory because of high background staining. The tumor cells were also negative for CD5, CD7, CD8, TIA-1, CD25, CD30, CD56, CD68, CD163, myeloperoxidase, CD33, CD99, TdT, CD34, CD117, S100, and EMA.
Flow cytometry studies were carried out on a portion of the excisional biopsy but showed predominantly debris with no evidence of a monoclonal B-cell population. A PCR assay for IgH gene rearrangements showed an oligoclonal pattern, and a PCR assay for TCR-g gene rearrangements was notable for poor amplification, although there was a significant polyclonal component.
The patient's mental and respiratory status waxed and waned over the course of his hospital stay. Shortly after diagnostic tissue was obtained, the patient's condition abruptly declined, and he was transitioned to comfort care. He died approximately 2 months from the reported onset of symptoms.
DISCUSSION
Here, we report an intravascular lymphoma that is associated with both EBV and HHV-8 viral infection, which joins a small but growing family of LPDs driven by EBV and HHV-8 coinfection. EBV-positive and HHV-8positive lymphomas are often clinically aggressive in immunocompromised individuals and include PEL presenting as an effusion [2] [3] [4] or mass lesion, 5,6 germinotrophic lymphoproliferative disorder, 10 rare cases of multicentric Castleman-associated plasmablastic lymphoma or microlymphoma, 12,13 a cutaneous plasmablastic lymphoma arising in a transplant patient, 17 and rare large B-cell lymphomas. 18 Lymphomas in this family tend to have large, atypical cells with an unusual phenotype. 4, 7, 9 The tumor cells typically lack pan B-cell markers such as CD20, CD19, and CD79a but do show expression of 1 or more activation or plasma cell markers including MUM-1, CD138, or CD38. 1, 10, 12, 18 This case of EBV-positive and HHV-8-positive intravascular lymphoma also demonstrated aberrant expression of T-cell markers, which can occasionally be seen in EBV/HHV-8-positive lymphomas. 6, 8, 15 The expression of T-cell antigens on tumor cells initially raised the possibility that the biopsy findings represented a primary T-cell intravascular lymphoma.
Although most intravascular lymphomas are large B-cell lymphomas, T-cell and NK/T-cell intravascular lymphomas have also been reported. NK/T-cell intravascular lymphomas are the most common of the intravascular T-cell lymphomas and are characterized by frequent skin involvement and an aggressive clinical course. These express cytotoxic markers including CD8, TIA-1, and CD56, and most are EBV positive. [22] [23] [24] The lack of cytotoxic T-cell marker expression and clonal rearrangement of the TCR-g gene argues against a diagnosis of NK/T-cell intravascular T-cell lymphoma in this case. There have also been rare reports of intravascular anaplastic large cell lymphomas (ALCLs). [25] [26] [27] These lymphomas express CD4 and CD30 but are ALK and EBV negative and typically form a discrete cutaneous mass with tumor cells localized to the lymphatics. Intravascular ALCLs are reported to have a relatively indolent clinical course. Finally, there are rare reports of skin lesions that contain a proliferation of atypical CD30-positive cells within small vessels, and these cases are thought to represent a reactive process. 28 CD30, which is not a lineage-associated antigen, is not expressed in this case, making a diagnosis of intravascular ALCL or a reactive proliferation unlikely. 29 Although the immunophenotype of the tumor cells is consistent with PEL, we are unable to definitively assign a lineage to this intravascular lymphoma. The neoplastic cells are largely negative for B cell-specific antigens, there is no evidence of a B-cell clone on flow cytometric analysis, and IgH gene rearrangement studies did not reveal a clone. In addition, although the tumor cells expressed dim CD3 and CD4, TCR gene rearrangement studies showed no definitive evidence of a clonal T-cell population. Molecular studies were hampered by the sparse distribution of tumor cells and admixed inflammatory cells, which also precluded microdissection. Despite our inability to demonstrate a B-cell or T-cell clone, the immunophenotype is typical of PEL, which is currently considered a mature B-cell lymphoma despite the fact that it characteristically lacks expression of B-cell antigens as well as surface and cytoplasmic immunoglobulin. 1, 2, 30 It is noteworthy that PEL can also show aberrant expression of T-cell antigens and may even demonstrate rearrangement of both TCR and immunoglobulin genes or TCR genes alone. [31] [32] [33] Another feature of the tumor in this patient was the finding of extensive organizing thrombi within the small vessels, which surrounded and obscured the neoplastic cells. Although fibrin thrombi associated with hemorrhage and necrosis have occasionally been observed in both IVLBCL 1, 34 and intravascular cytotoxic T-cell lymphoma, 35 the thrombi were particularly pronounced in this HHV-8-positive and EBV-positive lymphoma. Thrombosis in the setting of intravascular lymphoma could further accelerate end-organ ischemic damage, leading to a more rapid and aggressive disease course. The mechanism underlying the formation of thrombi in lymphoma is unclear but may relate to production of cytokines by the tumor cells, which could also be potentiated by viral infection. In particular, IL-6, an analog of which is produced by HHV-8 viral infection, is known to promote coagulation without affecting fibrinolysis. 36 In one study of the risk factors for developing thrombotic complications in HIV-infected individuals, malignancy in the form of Kaposi sarcoma was one of the most frequently identified risk factors. 37 Although the exact mechanism of thrombosis in this case is uncertain, it is intriguing to speculate that the production of viral cytokines by HHV-8-infected cells contributed to the formation and had dim expression of CD79a (C and D), but were negative for CD20 (E), CD19, Pax-5, and CD138 (not shown). The tumor cells also expressed dim cytoplasmic CD3 (F), dim CD4 (G), and CD45-RO (not shown) but were negative for CD5, CD7, CD8, CD56, and TIA-1 (not shown). An immunostain for HHV8 (LANA-1) (H) and an ISH for EBV (EBER) (I) were positive in the neoplastic cells, which were restricted to the intravascular compartment. J, The tumor cells had a high Ki-67 proliferation index. The neoplastic cells (K, H&E) also showed expression of viral IL-6 (L). H&E indicates hematoxylin and eosin. of fibrin thrombi, and the fact that viral IL-6 is expressed by the tumor cells provides support for this hypothesis. The diagnosis of intravascular lymphoma in this patient required sampling of deep subcutaneous adipose tissue. The excisional biopsy was prompted by the radiographic findings and insufficient sampling on fineneedle aspiration. Even when no overt skin findings are present, blind skin biopsies have been shown to be a relatively sensitive way to diagnose intravascular lymphoma. [38] [39] [40] [41] [42] In one case series, 10 of 12 consecutive patients with a known diagnosis of intravascular lymphoma had evidence of lymphoma on skin biopsies, both in lesions and in areas with healthy-appearing skin. 39 Several studies have shown that IVLBCL tends to involve the vessels of the subcutaneous fat but not the dermis. 38, 40 These studies and the findings in this case illustrate that a superficial shave or punch skin biopsy may not be sufficient to diagnose intravascular lymphoma.
The relative risk of developing a B-cell lymphoma is increased by a factor of at least 80-fold in patients with HIV as compared with the general population. 1 The incidence of some types of viral-driven neoplasms in HIVpositive individuals has decreased dramatically with the introduction of highly active antiretroviral therapy, including primary central nervous system lymphoma, which is nearly uniformly EBV positive. [43] [44] [45] However, the incidence of other types of lymphoma has been relatively unaffected, including Hodgkin and Burkitt lymphoma. 43, 45 Reductions have also been seen in the frequency of neoplasms, such as Kaposi sarcoma, that arise in the presence of very low CD4 counts. 45 Interestingly, lymphoproliferative disorders with HHV-8 and EBV coinfection may arise in patients with well-controlled HIV viral loads and CD4 counts >500, as occurred in this case. 3 Thus, as patients live longer with HIV infection and fewer deaths are attributable to opportunistic infections or other acquired immunodeficiency syndrome-defining illnesses, HHV-8-driven and EBV-driven lymphomas may become increasingly prominent.
In summary, EBV and HHV-8 are recognized as important contributors toward lymphomagenesis, but only rare LPDs involving coinfection by these viruses have been described. The findings in this case suggest that inhibition of IL-6 signaling could provide a potential strategy for the amelioration of symptoms in some patients with HHV-8 lymphomas 46 and also demonstrate that HHV-8-positive and EBV-positive lymphomas can present not only as effusions or solid tumor masses but also as intravascular lymphomas.
